Renal Abnormalities in Microfilaremic Patients with Bancroftian Filariasis

Dreyer, Gerusa; Ottesen, Eric A.; Galdino, Eliane; Andrade, Luiz Dias de; Rocha, Abraham; Medeiros, Zulma; Moura, Izolda; Casimiro, Ilecir; Béliz, Fátima; Coutinho, Amaury

doi:10.4269/ajtmh.1992.46.745

Cited by 92 publications

(54 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the patient did not have any renal symptoms, microscopic hematuria and proteinuria have been documented in 45% of untreated microfilaremic patients [1]. Both deposition of immune complexes in the glomerular basement membrane and mechanical damage to glomeruli by circulating microfilariae are believed to account for the hematuria in these cases [10].…”

Section: Discussionmentioning

confidence: 99%

Disseminated Microfilaremia Associated with Lung Cyst and Empyema: An Autopsy Report

et al. 2009

View full text Add to dashboard Cite

Clinical manifestations of extralymphatic disease caused by filariasis are varied and range from symptoms due to tropical pulmonary eosinophilia to hematuria, proteinuria, splenomegaly, and rarely arthritis. Disseminated microfilaremia in association with loculated lung cyst and empyema is of rare occurrence and to the best of our knowledge has not been documented in the literature so far. We report here a case of disseminated microfilaremia due to Wuchereria bancrofti infection accompanied by a lung cyst and empyema in a 21-year-old Indian man.

show abstract

Section: Discussionmentioning

confidence: 99%

Disseminated Microfilaremia Associated with Lung Cyst and Empyema: An Autopsy Report

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Parasitic antigens were demonstrated in glomeruli from 9 of 18 patients with proliferative glomerular disease due to onchocerciasis, supporting this hypothesis about the pathogenesis in these 9 patients (55). Treatment of patients with bancroftian and onchocerciasis infection was shown to increase the incidence of hematuria and proteinuria, which remained after treatment (24,33,56). This is an argument in favor of the pathogenicity of immune complexes, since it is presumed that there is an increase in the number of circulating immune complexes during treatment due to the disintergration of parasites.…”

Section: Pathogenesis Of Glomerular Diseasementioning

confidence: 98%

“…Several studies have recently shown a clear association of filariasis and glomerular disease (24,46,55,57). This association is often difficult to establish due to frequent coinfections (hepatitis B and malaria).…”

Section: Filarioideamentioning

confidence: 99%

“…The different parasites are identified by their location, periodicity, morphological characteristics, and clinical presentation of the disease they cause. Wuchereria bancrofti and Brugia malayi cause lymphatic filariasis, which is characterized by lymphatic blockade and elephantiasis but is asymptomatic in many cases (24). These infections are endemic in Africa, Southeast Asia, and the coastal planes of South America.…”

Section: Filarioideamentioning

confidence: 99%

See 1 more Smart Citation

Glomerulopathy associated with parasitic infections

Velthuysen

1996

Parasitology Today

View full text Add to dashboard Cite

“…Por outro lado, o efeito microfilaricida da DEC a curto prazo é dose dependente 3 . Assim, nos portadores de hematúria filarial 28 , o tratamento de 12 dias deve ser repetido tantas vezes quantas forem necessárias para levar ao desaparecimento das microfilárias circulantes. Ocorrendo falha no tratamento com a DEC (pelo fato de o paciente apresentar vermes adultos não susceptíveis e continuar produzindo microfilárias) e havendo reaparecimento da hematúria, deve-se lançar mão da co-admininistração da DEC com a ivermectina* * (6mg/kg e 400µg/kg de peso, respectivamente).…”

Section: Tratamento Quimioterápico Antifilarialunclassified

Recomendações para o tratamento da filariose bancroftiana, na infecção e na doença

Dreyer

Norões

2002

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

Resumo As bases para se instituir o tratamento da filariose linfática são: prevenir, reverter ou diminuir a progressão da doença e interromper a transmissão do parasita. A escolha das medidas mais adequadas para o tratamento dos pacientes portadores de filariose linfática requer o conhecimento das diversas manifestações clínicas, assim como os seus diferentes mecanismos patogênicos. No passado, o tratamento da filariose era baseado somente na prescrição da droga antifilarial, porém, para os pacientes apresentando as manifestações agudas ou crônicas da doença, é imperativo que outras medidas sejam indicadas, incluindo higiene e dieta. Assim, essa nova visão multidisciplinar terapêutica é tão ou mais importante do que o início imediato da terapia antifilarial. Independentemente da manifestação clínica do paciente, três componentes estão agora indicados: 1) os cuidados clínicos e higiênico-dietéticos específicos para as diversas manifestações clínicas, 2) a educação e o suporte psicológico e finalmente 3) o tratamento quimioterápico com a dietilcarbamazina (DEC) ou a combinação de DEC e ivermectina. Os autores descrevem também as eficácias relativas macro e microfilaricidas da dietilcarbamazina e da ivermectina sozinhas ou em combinação usadas em programas de tratamento em massa para interrupção da transmissão e comentam sobre a introdução do uso da higiene em programas de saúde pública para a prevenção do linfedema. Palavras-chaves: Controle. Tratamento. Dietilcarbamazina. Ivermectina. Bancroftose. Elefantíase.Abstract The goals of treatment for lymphatic filariasis are: to prevent, reverse, or halt progression of disease; and to interrupt transmission of the parasite. Selecting the appropriate therapy for the patient with lymphatic filariasis requires knowledge of the various clinical features of filarial disease and their pathogenesis. In the past, treatment of lymphatic filariasis has focused primarily on antiparasitic chemotherapy; however, for many of the acute and chronic manifestations of lymphatic filariasis, it is now clear that supportive or other forms of clinical care are even more important than antiparasitic medication in order to prevent worsening of the disease. Regardless of the clinical manifestations of filarial disease in a particular patient, the following three components of treatment should, in general, be considered: supportive or disease-specific clinical care (including higiene and diet), patient education and counseling and finally, antiparasitic chemotherapy with diethylcarbamazine (DEC) and/or the combination of DEC with ivermectin. The authors also describe the proportional efficacy of diethylcarbamazine and ivermectin, alone or in combination, for use in mass treatment aiming at transmission interruption and the use of hygiene as a public health approach for lymphedema prevention. Key-words: Control. Treatment. Diethylcarbamazine. Ivermectin. Bancroftian filariasis. Elephantiasis. Nos últimos anos, a filariose linfática tem surgido como um problema crescente em saúde pública em vária...

show abstract

Renal Abnormalities in Microfilaremic Patients with Bancroftian Filariasis

Cited by 92 publications

References 0 publications

Disseminated Microfilaremia Associated with Lung Cyst and Empyema: An Autopsy Report

Disseminated Microfilaremia Associated with Lung Cyst and Empyema: An Autopsy Report

Glomerulopathy associated with parasitic infections

Recomendações para o tratamento da filariose bancroftiana, na infecção e na doença

Contact Info

Product

Resources

About